Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi John,
That is correct, we are currently OTC grey market and moving up to the OTCQX, hopefully in the next couple of weeks. Our main listing is on the Canadian Stock Exchange under ticker EPW.
The company is currently implementing a US national CBD strategy to license, distribute, and sell our own branded CBD products.
We also have a patient database of over 120k patients in Washington and Oregon and have a flagship clinic in Chicago. We also have plans to open clinics state by sate employing an M&A strategy by combining groups of clinics and operating them under the Empower brand.
The company is also looking to JV with operators and license holders in various stages to integrate the grow, distillate, product, and clinic/dispensary market. We call this the seed to sale model.
Please let me know if you have any further questions.
Regards,
Steven
-------- Original Message --------
Subject: OTC
From: "JohnCM"
Date: Sat, October 06, 2018 8:29 pm
To: <mark@pointerpr.com>
Empower Clinics OTC ticker currently grey sheet?
Future plans?
John
$CIIX Cannabidiol (hereinafter referred to as CBD) industry. The company focuses on investing in research and development to produce CBD drugs and nutritional supplements to help patients with epilepsy, Alzheimers neuropathy out of the pain. Our company has established Chinese CBD online store to provide CBD nutrition, cosmetics and health care products and their wholesale and retail services. http://www.chinesecbdoil.com/english/about-us.chtml
$CIIX CBD Oil
CBD oil is gaining popularity in North America and is considered a food nutrient delivering the benefits of cannabinoids without the psychotropic effects of THC. It has already been legalized in the 50 states of the U.S., and can also be exported to more than 40 countries including China.
http://chineseinvestors.com/opportunities-in-cbd/
$CIIX Cannabidiol (CBD) is one of the most important healing substances in the hemp plant with a strong anti-inflammatory effect without a psychotropic (narcotic) effect.
http://chineseinvestors.com/opportunities-in-cbd/
"Sunniva is my dog"
I'm just taking a long investor view on sunniva and really don't care where it goes on the way to my target. I see that massive, and I mean massive grow coming together nicely.
Going from not growing to growing 13 football fields, or whatever that is there, will be a significant increase in revenue and value.
Same for the Canada campus which is just getting started.
Totally a dog right now and seems to get no love. Kinda like PAT at $1 after it had been $2.
Worst ever. Citron causes Investor Damages with fake news, then tries to trump up a lawsuit against the company for... wait for it... Investor Damages caused by the company's fake news.
all just to aid a short attack that citron admits to.
Classic citron/left tactics. Seen it before a thousand times.
Yet, it's quite often effective at least for the short term.
Vultures ...
Ambulance chasers ...
Dropping shit during "quiet period."
Well, with the class action lawsuit announced today, I suppose weakness will provide us with a dip... maybe for a while.
really hard to say if any of that bullshit will get any traction.
Thanks for sharing.
I don't think so. Sunniva is my dog. Where does Namaste head from $1.60?
this article talks about what they do
and they don't like it:
"So after opening up the High Times IPO and taking a big sniff, it’s hard to believe it contains pungent smelling skunk buds. There are far more seeds and stems in that bag than we like so we’ll pass. With that said, the amount of irrational exuberance we’ve seen around the whole marijuana theme has been mind boggling. Just be aware that if this IPO happens and the stock price jumps 100% on opening day, that’s not indicative of future performance. The High Times Holding Group has a long road ahead of them if they hope to get out of the red and into the black by both increasing revenues and decreasing costs, all while making sure they continue paying interest on all that debt they’ve accumulated."
https://www.nanalyze.com/2018/02/high-times-ipo/
buybuybuy $11 !!!!!!!! Love the magazine BUYBUYBUY
I do not get the business model. I do like the magazine though.
High Times Private Offering
hadn't seen this mentioned here yet. Been out there for a while.
applied for listing nasdaq. HITM is the ticker if they get approved.
You can buy shares for $11 ahead of the maybe listing.
Regulation A report
https://www.sec.gov/Archives/edgar/data/1714420/000121390018012374/0001213900-18-012374-index.htm
https://www.sec.gov/Archives/edgar/data/1714420/000121390018000990/f1a2018a1_hightimeshold.htm
https://hightimesinvestor.com/
https://hightimes.com/news/high-times-ipo-first-accept-bitcoin-ethereum/
https://hightimes.com/business/guide-regulation-cannabis-investments/
https://cannabisnow.com/high-times-shares/
https://www.mediapost.com/publications/article/325255/high-times-ipo-backed-by-6000-investors.html
https://www.nanalyze.com/2018/02/high-times-ipo/
SEDAR
Cannabis Industry's Most Recognized Consumer Packaged
Goods Brand Going Public, Expanding Global Operations
Denver-based Dixie Brands, Inc. Targets Going Public On the Canadian Securities Exchange In
October, Plans Significant Expansion
DENVER, Oct. 1, 2018 / -- Dixie Brands, Inc. (Dixie) signed a definitive merger agreement on
September 28, 2018 in connection with its proposed public listing on the Canadian Securities
Exchange (CSE). Pending approval from the CSE, Dixie will complete a reverse takeover (RTO)
of a Canadian public company, Academy Explorations Limited (Academy) and will be
subsequently renamed Dixie Brands (USA) Inc. Both Academy and Dixie have received board
and shareholder approval for the RTO. As a result, Dixie will boast the largest global footprint of
infused product manufacturing and distribution facilities of any brand in the cannabis space.
"The Federal legalization of marijuana in Canada is further proof that cannabis is no longer a fringe
conversation or product. By going public on the CSE, we're investing in Dixie's future for
continued growth with a focus on quality, product innovation and scale," says Dixie CEO Chuck
Smith.
Simultaneously with the finalization of the documents in connection with the RTO, Dixie closed
its Series C fundraising round of approximately $25 million. The Series C round was originally
offered as a non-brokered private placement for $20 million, however, due to positive investor
demand, Dixie increased the maximum offering amount to $25 million with board and shareholder
approval.
"The financing round we have just closed will provide resources for Dixie to expand our brand
throughout the U.S. and into Canada," Smith states. "Dixie has been a leader in the cannabis
industry since its inception. We have nine years of experience developing intellectual property and
building a brand that creates an incredible platform for our company and shareholders. We look
forward to providing the same safe, high quality, and consistent product to patients and adult-use
consumers throughout the U.S. and Canada."
Dixie is currently operating in four states (Colorado, California, Nevada, and Maryland) and has
international distribution and manufacturing partners in Australia and Canada. Dixie plans to
expand into four to six additional states in 2019 through partnerships with licensed and regulated
producers in each state. Already the owner of the largest award-winning, THC-infused product
line in the industry, Dixie has recently expanded its hemp-based offerings by introducing Aceso
Wellness, a human dietary supplement line, and Therabis, a pet food supplement portfolio, at the
end of 2016. These highly regarded products are available through brick-and-mortar locations and
e-commerce in all 50 states, and internationally.
As a result of the additional capital recognized by the Series C raise and future access to capital in
the public markets, Dixie will expand its controlled manufacturing and distribution footprint
throughout the U.S., and invest in automated production to increase manufacturing scale and
efficiency. Additionally, Dixie will invest in continued product innovation and development in
line with mainstream consumer trends and ever-increasing demand from wide ranging
demographics.
The New Frontier in Canada
A recent parliamentary vote in Canada legalized marijuana across the country. In 2018, Dixie
entered into a Canadian license agreement with Auxly Cannabis Group Inc. (Auxly), a vertically
integrated global cannabis company. Under the agreement, Auxly will work closely with the Dixie
team to co-develop innovative products for the adult-use recreational Canadian market.
Dixie products will be developed and manufactured at Auxly's wholly-owned Canadian-licensed
dealer, Dosecann Inc., a company led by a world-class team of food scientists, extraction
specialists and product innovators. Dosecann operates out of a 42,000 square foot facility, purposebuilt
for extraction and the research, development and manufacturing of cannabis products.
Dosecann is located in the BioCommons Research Park in Charlottetown, PEI where it benefits
from the thriving biotech community that PEI has attracted over the past decade. Dosecann will
serve as Dixie's hub of cannabis research and innovation.
Dixie's House of Brands
Dixie started with a single product, the Dixie Elixir, a THC-infused soda, and now offers more
than 30 different categories across more than 100 individual products – one of the broadest THC
product lines in the industry. The award-winning company is a trailblazer in the rapidly expanding
and evolving cannabis landscape. Brands that are distributed under the Dixie Brands umbrella
include:
• Dixie, our namesake line that includes premium and award-winning THC-infused
beverages, confections, concentrates, tinctures, and topicals
• Synergy, a variety of THC-infused products which also harnesses the benefits of CBD, the
cannabinoid most often hailed for its anti-anxiety and anti-inflammatory benefits
• Mindset, an array of connoisseur-grade combustible cannabis products including
concentrates, pre-rolls, and flower
• Dr. Stash, a price-centered brand that focuses on scalable products that have the ability to
quickly be brought to market
In 2016, Dixie launched two new standalone brands to harness the benefits of CBD, a nonpsychoactive
compound found in hemp that is commonly hailed for its anti-anxiety and
anti-inflammatory benefits: Therabis and Aceso Wellness. Both the Aceso and Therabis brands
have been sold through traditional retail and online since their inception.
• Aceso, a suite of "hemp 2.0" products designed to provide general wellness and relief from
minor aches and pains as well as combat mild-anxiety
• Therabis, an all-natural hemp-based pet supplement formulated in conjunction with an
experienced veterinarian and designed to provide pets with relief from itching and mildanxiety
as well as providing greater joint mobility
Education, Quality & Innovation
Dixie has established itself as the trusted source for innovative, safe, effective and delicious
cannabis products, leading to features on 60 Minutes, CNBC, MSNBC, Fast Company and many
more. The company is built and managed as a commercial food manufacturer with years of
standard operating procedure development and unmatched scaling capabilities. Dixie handcrafts
every product with pure-extracted THC and exceeds mandated regulation by triple lab testing
every product. The company boasts extensive expertise in emulsification, formulation, packaging
and regulatory compliance.
Additionally, Dixie leads the way in working with legislators at the state and national level, driving
reform and educational initiatives, as well as serving as founding members of Colorado Leads, the
New Federalism Fund and the Cannabis Trade Federation.
A listing statement with information about Dixie and prepared in accordance with the policies of
the CSE will be available on SEDAR at sedar.com. The merger agreement will also be posted on
SEDAR on Academy's home page.
To find out more about Dixie's innovative products, or about how Dixie is building the future of
cannabis, please visit us at dixiebrands.com.
Colorado Cannabis Company Dixie Brands to Go Public in Canada
July 26, 2018 at 10:23 am
Published by NCV Newswire
Award Winning Cannabis Infused Products Company Dixie Brands to Go Public via Academy Explorations
TORONTO, July 26, 2018 (GLOBE NEWSWIRE) — Academy Explorations Limited (“Academy” or the “Company”) is pleased to announce that it has entered into a letter of intent (the “LOI”) dated July 26, 2018 with Colorado-based Dixie Brands, Inc. (“Dixie”) whereby the parties will complete a business combination by way of a transaction that will constitute a reverse takeover of the Company by Dixie (the “Transaction”). Pursuant to the Transaction, the Company will apply to list on the Canadian Securities Exchange (the “CSE”).
The resulting issuer that will exist upon completion of the Transaction (the “Resulting Issuer”) will change its business from mining to the cannabis industry and intends to apply for listing of its common shares on the CSE. The final structure of the Transaction will be determined by the parties following receipt of tax, corporate and securities law advice and is subject to the approval of the CSE. The Transaction is an arm’s length transaction.
Upon the closing of the Transaction (the “Closing”) and after giving effect to the maximum Private Placement and the Debt Conversion (each defined below), it is expected that former shareholders of Dixie will hold approximately 95% of the common shares of the Resulting Issuer (the “Resulting Issuer Shares”) and current shareholders of the Company will hold approximately 5% of the Resulting Issuer Shares (on a fully-diluted basis).
Dixie Brands, Inc. (“Dixie”) is a marketing, intellectual property and product development company designed to build and manage the expansion of the Dixie product portfolio worldwide. What started as a Dixie Elixir beverage in 2010, as part of the legal medical marijuana market in Colorado, has grown to be the first true national consumer package goods company in the cannabis industry.
Dixie has three portfolio companies under its umbrella: Dixie Elixirs & Edibles, Aceso Wellness (Hemp-derived CBD based human dietary supplement), and Therabis (Hemp-derived CBD based pet food supplement). The company currently operates in four U.S. states with an aggressive expansion plan for 2019. Dixie has also executed a license agreement with Auxly Cannabis (“Auxly”) in May of 2018. This agreement permits Auxly to exclusively produce and distribute Dixie branded products throughout Canada.
Dixie’s expansion strategy will be to control manufacturing and distribution in all markets where it participates while simultaneously building a global brand known for its quality and efficacy.
Dixie’s sustainable competitive advantages include:
Brand awareness:
Most recognizable brand in the cannabis industry.
Intellectual property:
Eight years of formulations, standard operating procedures, and emulsification technology.
Multi-state regulatory experience: packaging, labeling, regulatory compliance expertise.
Patent pending technology for Aceso and Therabis.
Innovation:
Broadest portfolio of consumer product delivery systems.
11 delivery systems across over 100 Stock Keeping Units (“SKUs”).
Manufacturing & Distribution:
By end of 2019, Dixie expects to have the broadest controlled manufacturing and distribution footprint of any brand in the U.S. cannabis market delivering a standardized, reliable, and consistent product to end consumers in all markets.
We are delighted to take the iconic Dixie Elixir, as well as our other consumer focused brands, to the public capital markets in order to bring these well recognized and highly rated products to enthusiastic consumers across the U.S., as well as to Canada and other international markets.
Chuck Smith, President and CEO of Dixie
The Canadian capital markets have proved to be an important and critical source of growth funding for U.S. cannabis companies. We are preparing for and anticipate a Q4, 2018 public offering on the CSE which will fund revenue generating production, distribution and consumer marketing programs to support our global expansion.
Dixie’s respected industry profile generates consistent business development opportunities, including; celebrity brands, cannabis brands, and strategic expansion partnerships. The financial strength of the company will enable it to take advantage of more of these accretive deals.
Dixie Private Placement
Dixie intends to complete a private placement (the “Private Placement”) prior to Closing of Dixie Shares and warrants (“Dixie Warrants”) for aggregate gross proceeds of between US$12,000,000 and US$20,000,000, including the conversion of approximately US$2,000,000 of debt to be exchanged for Dixie common shares (“Dixie Shares”) at the same deemed value of Dixie as the Private Placement, at a price equal to the fully diluted equity capitalization of Dixie prior to the Private Placement valued at US$80,000,000. Each Dixie Warrant shall entitle the holder thereof to acquire one Dixie Share for US$13.95, at an approximate valuation of US$150,000,000, exercisable for one year.
Share Consolidation and Exchange of Securities
Pursuant to the terms of the LOI, the Company will effect a consolidation (the “Share Consolidation”) of its issued and outstanding common shares (the “Academy Shares”) prior to Closing on a 4:1 basis resulting in approximately 6,641,808 Academy Shares outstanding on a post-Share Consolidation basis. The 400,000 issued and stock options of Academy (“Academy Options”) will be consolidated into 100,000 Academy Options. Each Academy Option will be exercisable for one Academy Share at an exercise price of C$0.08 per share on a post-Share Consolidation basis until July 5, 2021.
In addition, the Company will, prior to Closing, create a new class of non-participating voting shares which will have the right to a single vote at meetings of the holders of Academy Shares but will have no right to dividends or assets on wind-up (those shares, the “NPV Shares”; the creation of those shares, the “NPV Share Creation”).
In accordance with the terms of the Transaction, the holders of the issued and outstanding shares of common stock in the capital of Dixie (the “Dixie Shares”) will be issued approximately 10.45 Academy Shares in exchange for every one (1) Dixie Share held immediately prior to the completion of the Transaction (the “Exchange Ratio). The deemed exchange price for the Academy Shares will be approximately C$1.00 per Academy Share, or such other price as permitted by governing regulatory bodies.
Outstanding convertible securities of Dixie (the “Dixie Convertible Securities”) will either automatically adjust in accordance with their terms such that, following the completion of the Transaction, the holders of Dixie Convertible Securities will acquire Resulting Issuer Shares, or will be replaced with equivalent convertible securities of the Resulting Issuer entitling such holders to acquire Resulting Issuer Shares on the same terms as the Dixie Convertible Securities that they will replace and, in each case, adjusted to reflect the Exchange Ratio and exchange price. Certain Dixie Convertible Securities held by the management team and employees will be exchanged for NVP Shares.
Academy Shareholder Meeting
Prior to the Closing, Academy will call a meeting of its shareholders for the purpose of approving, among other matters (collectively, the “Academy Meeting Matters”):
a change of name of the Company to “Dixie Brands Inc.” or such other name as is directed by Dixie and acceptable to applicable regulatory authorities effective upon Closing;
the Share Consolidation;
the NPV Share Creation;
an amendment to its articles of incorporation to remove its authorized class of special shares, of which there are presently none outstanding;
the approval of a new stock option plan to be effective upon Closing;
the election of a slate of directors appointed by Dixie, which elections will be effective upon Closing;
the appointment of a new auditor; and
if required by governing regulatory bodies, the approval of the Transaction.
The Transaction is an arm’s length transaction. Academy will, however, prepare and file with the CSE a CSE Form 2A listing statement or other principal disclosure document (the “Listing Statement”) providing comprehensive disclosure on Dixie and the Transaction in connection with the CSE listing.
Management of the Resulting Issuer
Upon closing of the Transaction, all of Academy’s current directors and executive officers will resign and the board of directors of the Resulting Issuer will, subject to the approval of governing regulatory bodies, consist of between 3 and 7 directors, each of which shall be appointed by Dixie in its sole discretion. All of the executive officers shall be replaced by nominees of Dixie, all in a manner that complies with the requirements of governing regulatory bodies and applicable securities and corporate laws.
Details of insiders and proposed directors and officers of the Resulting Issuer will be disclosed in a further news release.
Closing Conditions
The completion of the Transaction is subject to a number of conditions, including but not limited to the following:
the execution of a definitive agreement;
completion of mutually satisfactory due diligence;
completion of the Academy Meeting Matters;
and receipt of all required regulatory, corporate and third party approvals, including approvals by governing regulatory bodies, the shareholders of Academy, applicable U.S. governmental authorities, the CSE and the fulfilment of all applicable regulatory requirements and conditions necessary to complete the Transaction.
Further information
Further details about the Transaction and the Resulting Issuer will be provided in a comprehensive news release when the parties enter into the definitive agreement.
Investors are cautioned that any information released or received with respect to the Transaction in this press release may not be complete and should not be relied upon. Trading in the common shares of the Company should be considered highly speculative.
The securities to be issued in connection with the Transaction have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in Regulation S promulgated under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Completion of the Transaction is subject to a number of conditions, including but not limited to, CSE acceptance and if applicable, disinterested shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the management information circular or Listing Statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Academy should be considered highly speculative.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
About Academy Explorations Limited
Academy Explorations Limited previously operated as a mineral exploration company but presently has no current activities or operations.
About Dixie Brands, Inc.
Dixie Brands, Inc., which has been formulating award-winning THC and CBD-infused products since 2009, is expecting to double its manufacturing and distribution capabilities in 2019 in the US as well as expand internationally, including Canada. They lead the global industry in the development, packaging design, product innovation and quality control for the commercial production of cannabis infused products. While the company started with a single flagship product, the Dixie Elixir (a THC-infused soda), it is now one of the industry’s most recognized consumer brands, expanding to over 100 products across more than 30 different product categories representing the industry’s finest edibles, tinctures, topicals and connoisseur grade extractions, as well as world-class CBD-infused wellness products and pet dietary supplements. Dixie’s executive team has been instrumental in the formation of the marijuana industry for recreational and medicinal use, serving as founding members on several national regulatory and business-oriented industry organizations. To find out more about Dixie’s innovative products, or about how Dixie is building the future of cannabis, visit www.dixiebrands.com.
Acreage will attract plenty of attention.
Anyone know the IPO date for Acreage?
What are your thoughts on the REG A+ High Times offering?
Is there any IPO or existing stock specializing in THC based beverages (besides HEXO, NBEV, IGC)
$CIIX cbd
California Cannabis Store $CIIX
Well you can't really go wrong there. Been squirreling shares of that pig for awhile now, only a matter of time. It has been the gift that keeps on giving. Hopefully it starts to gain some traction again soon!
I did not ...
I bought more CV Science.
Did you score some? I was able to call up and snag a few thousand shares. I guess we’ll see if there up for the challenge. Looks promising.
You know what’s funny? I don’t see auxly or Namaste on that list.....hmmmm?
https://www.otcmarkets.com/stock/MLCPF/profile
Grey market.
I will follow closely.
Only Canadian .. for now.
Still can't find otc
Yes I will buy at open. Probably by phone. Last bought deal at 0.85
Are you gonna pick some up? Do we have to call in trade like with Charlotte's? Been waiting a year for them to go public, do you think they will do well being an oil only processor, or just a momentum trade?
Not yet.
I will have to buy the IPO on the TSXV exchange.
PRESS RELEASES
EVENTS
IN THE NEWS
MediPharm Labs Corp. (formerly POCML 4 Inc.) Announces Closing of Business Combination With MediPharm Labs Inc. and Anticipated Trading Date of October 4, 2018
Oct 2, 2018
POCML 4 Inc. Files Filing Statement in Connection With Proposed Qualifying Transaction With MediPharm Labs Inc.; Expects to Commence Trading on TSXV Under the Ticker Symbol “LABS” on or About October 3, 2018
Sep 25, 2018
Up Cannabis Signs Supply Agreement with MediPharm Labs for Extraction
Sep 24, 2018
POCML 4 Inc. Receives Conditional Approval of Business Combination with MediPharm Labs Inc.
Sep 21, 2018
OCS Announces New Supply Agreements with Additional Licensed Producers and Accessory Suppliers
Sep 5, 2018
INDIVA Signs Cannabis Concentrate Program Agreement With MediPharm Labs
Sep 4, 2018
Cannabis Corporation Operating in Manitoba Announces Name and Four Locations
Aug 22, 2018
MediPharm Labs Continues to Strengthen Leadership Team for Growth
Aug 9, 2018
Pocml 4 Inc. Announces the Signing of Two Cannabis Concentrate Program Agreements by MediPharm Labs Inc.
Aug 8, 2018
Bonify Signs Cannabis Concentrate Program Agreement With MediPharm Labs Inc.
Looking for IPO price
POCML 4 Inc. Files Filing Statement in Connection With Proposed Qualifying Transaction With MediPharm Labs Inc.; Expects to Commence Trading on TSXV Under the Ticker Symbol “LABS” on or About October 3, 2018
TORONTO, Sept. 25, 2018
POCML 4 Inc. (TSXV: POCM) (the “Company”) is pleased to announce that it has filed on SEDAR its filing statement dated
effective September 24, 2018 (the “Filing Statement”) in connection with its proposed business combination with MediPharm
Labs Inc. (“MediPharm”), which will result in a reverse take-over of the Company by the shareholders of MediPharm (the
“Transaction”). Subject to satisfaction of all conditions and approvals, including the satisfaction of the conditions of the TSX
Venture Exchange (the “TSXV”), the Transaction is expected to close on or about October 1, 2018. The Company expects
that the common shares of the Company as they exist after closing of the Transaction will commence trading on the TSXV
under the symbol LABS on October 3, 2018.
For further information, please refer to the Filing Statement on SEDAR at www.sedar.com, as well as the press releases of the
Company dated May 15, May 31, June 29, July 16, August 23, 2018 and September 21, 2018 available on SEDAR at
www.sedar.com.
About MediPharm Labs Inc.
Founded in 2015, MediPharm is a pioneer in the cannabis industry and has the distinction of being the first company in
Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes
Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from
our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows
MediPharm to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade
cannabis oil with a competitive advantage. MediPharm is research-driven and focused on downstream secondary extraction
methodology, distillation, and cannabinoid isolation and purification. MediPharm provides B2B contract processing of cannabis
to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to
qualified companies for sale under their own brand. In addition, MediPharm will supply raw materials, formulations, processing
and packaging for the creation of ready-to-sell advanced derivative products.
MediPharm Labs LABS.V
Fidelity has very little information, so far.
Trading
CSE exchange none DTC eligible utilizing agent $82.00 per trade
DTC eligible utilizing agent $32.95
DTC eligible listed on TSXV online trade $19.00
Do we know an OTC?
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |